Sacituzumab Govitecan Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 180 mg
Reference Brands: Trodelvy (USA/EU)
Category:
Oncology Cancer Care
Sacituzumab Govitecan is available in Injection
and strengths such as 180 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Sacituzumab Govitecan is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Sacituzumab Govitecan can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Sacituzumab govitecan is a targeted anticancer medicine used for the treatment of certain advanced or metastatic cancers. It is an antibody–drug conjugate designed to deliver chemotherapy directly to cancer cells. The drug consists of a monoclonal antibody that targets the Trop-2 protein, which is commonly found on the surface of many tumor cells, combined with a topoisomerase inhibitor that helps destroy cancer cells. By binding to Trop-2 and releasing the cytotoxic agent inside the tumor, sacituzumab govitecan helps reduce tumor growth while focusing treatment on cancer cells.
This therapy is used in patients with metastatic triple-negative breast cancer who have previously received other treatments. It is also approved for patients with metastatic hormone receptor-positive, HER2-negative breast cancer that has progressed after prior therapies. In addition, sacituzumab govitecan is used in certain cases of metastatic urothelial cancer when other treatment options have been used.
Because of its targeted delivery system, sacituzumab govitecan represents an important advancement in modern oncology treatments. It provides an additional option for patients with difficult-to-treat cancers and helps improve disease management in advanced stages of these conditions.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing